IMNM vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCM
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Immunome vs. Its Competitors
Immunome (NASDAQ:IMNM) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.
Immunome has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Immunome presently has a consensus price target of $23.33, indicating a potential upside of 172.90%. MoonLake Immunotherapeutics has a consensus price target of $74.50, indicating a potential upside of 59.36%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Immunome. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
44.6% of Immunome shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Immunome. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 1 mentions for Immunome. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Immunome's score of 0.70 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Immunome's return on equity.
Summary
MoonLake Immunotherapeutics beats Immunome on 10 of the 14 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 7/9/2025 by MarketBeat.com Staff
Free IMNM Stock Alerts